Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Effectiveness of casirivimab and imdevimab, and sotrovimab during Delta variant surge: a prospective cohort study and comparative effectiveness randomized trial

David T. Huang, Erin K. McCreary, J. Ryan Bariola, Tami E. Minnier, Richard J. Wadas, Judith A. Shovel, Debbie Albin, Oscar C. Marroquin, Kevin E. Kip, Kevin Collins, Mark Schmidhofer, Mary Kay Wisniewski, David A. Nace, Colleen Sullivan, Meredith Axe, Russell Meyers, Alexandra Weissman, William Garrard, Octavia M. Peck-Palmer, View ORCID ProfileAlan Wells, Robert D. Bart, Anne Yang, Lindsay R. Berry, Scott Berry, Amy M. Crawford, Anna McGlothlin, Tina Khadem, Kelsey Linstrum, Stephanie K. Montgomery, Daniel Ricketts, Jason N. Kennedy, Caroline J. Pidro, Rachel L. Zapf, Paula L. Kip, Ghady Haidar, Graham M. Snyder, Bryan J. McVerry, Donald M. Yealy, Derek C. Angus, Christopher W. Seymour
doi: https://doi.org/10.1101/2021.12.23.21268244
David T. Huang
1Department of Emergency Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
2Clinical Research Investigation and Systems Modeling of Acute Illness (CRISMA) Center, Department of Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
3Department of Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
MD MPH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: huangdt{at}upmc.edu
Erin K. McCreary
4Division of Infectious Diseases, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
PharmD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. Ryan Bariola
4Division of Infectious Diseases, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tami E. Minnier
5Wolff Center, UPMC, Pittsburgh, PA, USA
MS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard J. Wadas
1Department of Emergency Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Judith A. Shovel
5Wolff Center, UPMC, Pittsburgh, PA, USA
BSN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Debbie Albin
6Supply Chain Management/HC Pharmacy, UPMC, Pittsburgh, PA, USA
BS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Oscar C. Marroquin
7Clinical Analytics, UPMC, Pittsburgh, PA, USA
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kevin E. Kip
7Clinical Analytics, UPMC, Pittsburgh, PA, USA
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kevin Collins
7Clinical Analytics, UPMC, Pittsburgh, PA, USA
MBA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark Schmidhofer
8Division of Cardiology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mary Kay Wisniewski
5Wolff Center, UPMC, Pittsburgh, PA, USA
MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David A. Nace
9Division of Geriatric Medicine, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Colleen Sullivan
2Clinical Research Investigation and Systems Modeling of Acute Illness (CRISMA) Center, Department of Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
10Health System Office of Healthcare Innovation, UPMC, Pittsburgh, PA, USA
MHA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Meredith Axe
1Department of Emergency Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
BS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Russell Meyers
1Department of Emergency Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
MBA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexandra Weissman
1Department of Emergency Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William Garrard
7Clinical Analytics, UPMC, Pittsburgh, PA, USA
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Octavia M. Peck-Palmer
11Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alan Wells
11Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
MD DMSc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Alan Wells
Robert D. Bart
3Department of Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
12Health Services Division, UPMC, Pittsburgh, PA, USA
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anne Yang
13Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lindsay R. Berry
14Berry Consultants, Austin, TX, USA
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Scott Berry
14Berry Consultants, Austin, TX, USA
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amy M. Crawford
14Berry Consultants, Austin, TX, USA
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anna McGlothlin
14Berry Consultants, Austin, TX, USA
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tina Khadem
10Health System Office of Healthcare Innovation, UPMC, Pittsburgh, PA, USA
PharmD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kelsey Linstrum
2Clinical Research Investigation and Systems Modeling of Acute Illness (CRISMA) Center, Department of Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
10Health System Office of Healthcare Innovation, UPMC, Pittsburgh, PA, USA
MS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephanie K. Montgomery
2Clinical Research Investigation and Systems Modeling of Acute Illness (CRISMA) Center, Department of Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
10Health System Office of Healthcare Innovation, UPMC, Pittsburgh, PA, USA
MS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel Ricketts
2Clinical Research Investigation and Systems Modeling of Acute Illness (CRISMA) Center, Department of Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
MET
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jason N. Kennedy
2Clinical Research Investigation and Systems Modeling of Acute Illness (CRISMA) Center, Department of Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
3Department of Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
MS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Caroline J. Pidro
2Clinical Research Investigation and Systems Modeling of Acute Illness (CRISMA) Center, Department of Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
BS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rachel L. Zapf
5Wolff Center, UPMC, Pittsburgh, PA, USA
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paula L. Kip
5Wolff Center, UPMC, Pittsburgh, PA, USA
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ghady Haidar
4Division of Infectious Diseases, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Graham M. Snyder
4Division of Infectious Diseases, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bryan J. McVerry
15Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Donald M. Yealy
1Department of Emergency Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Derek C. Angus
2Clinical Research Investigation and Systems Modeling of Acute Illness (CRISMA) Center, Department of Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
3Department of Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
10Health System Office of Healthcare Innovation, UPMC, Pittsburgh, PA, USA
MD MPH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher W. Seymour
2Clinical Research Investigation and Systems Modeling of Acute Illness (CRISMA) Center, Department of Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
3Department of Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
10Health System Office of Healthcare Innovation, UPMC, Pittsburgh, PA, USA
MD MSc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

IMPORTANCE The effectiveness of monoclonal antibodies (mAbs), casirivimab and imdevimab, and sotrovimab, for patients with mild to moderate COVID-19 from the Delta variant is unknown.

OBJECTIVE To evaluate the effectiveness of mAbs for the Delta variant compared to no treatment, and the comparative effectiveness between mAbs.

DESIGN, SETTING, AND PARTICIPANTS Two parallel studies among patients who met Emergency Use Authorization criteria for mAbs from July 14, 2021 to September 29, 2021: i.) prospective observational cohort study comparing mAb treatment to no mAb treatment and, ii.) Bayesian adaptive randomized trial comparing the effectiveness of casirivimab-imdevimab versus sotrovimab. In the observational study, we compared eligible patients who received mAb at an outpatient infusion center at UPMC, to nontreated patients with a positive SARS-CoV-2 test. In the comparative effectiveness trial, we randomly allocated casirivimab-imdevimab or sotrovimab to patients presenting to infusion centers and emergency departments, per system therapeutic interchange policy.

EXPOSURE Intravenous mAb per their EUA criteria.

MAIN OUTCOMES AND MEASURES For the observational study, risk ratio estimates for hospitalization or death by 28 days were compared between mAb treatment to no mAb treatment using propensity matched models. For the comparative effectiveness trial, the primary outcome was hospital-free days (days alive and free of hospital) within 28 days, where patients who died were assigned -1 day) in a Bayesian cumulative logistic model, adjusted for treatment location, age, sex, and time. Inferiority was defined as a 99% posterior probability of an odds ratio <1. Equivalence was defined as a 95% posterior probability that the odds ratio is within a given bound.

RESULTS Among 3,558 patients receiving mAb, the mean age was 54 (SD 18 years), 1,511 (43%) were treated in an infusion center, and 450 (13%) were hospitalized or died by day 28. In propensity matched models, mAb treatment was associated with reduced risk of hospitalization or death compared to no treatment (risk ratio (RR)=0.40, 95% CI: 0.28–0.57). Both casirivimab and imdevimab (RR=0.31, 95% CI: 0.20–0.50), and sotrovimab (RR=0.60, 95% CI: 0.37–1.00) reduced hospitalization or death compared to no mAb treatment. Among patients allocated randomly to casirivimab and imdevimab (n=2,454) or sotrovimab (n=1,104), the median hospital-free days were 28 (IQR 28–28) for both groups, 28-day mortality was 0.5% (n=12) and 0.6% (n=7), and hospitalization by day 28 was 12% (n=291) and 12% (n=140), respectively. Compared to casirivimab and imdevimab, the median adjusted odds ratio for hospital-free days was 0.88 (95% credible interval, 0.70–1.11) for sotrovimab. This odds ratio yielded 86% probability of inferiority of sotrovimab versus casirivimab and imdevimab, and 79% probability of equivalence.

CONCLUSIONS AND RELEVANCE In non-hospitalized patients with mild to moderate COVID-19 due to the Delta variant, casirivimab and imdevimab and sotrovimab were both associated with a reduced risk of hospitalization or death. The comparative effectiveness of mAbs appeared similar, though prespecified criteria for statistical inferiority or equivalence were not met.

TRIAL REGISTRATION ClinicalTrials.gov: NCT04790786

Question In non-hospitalized patients with mild to moderate COVID-19 due to the Delta variant, what is the effectiveness of monoclonal antibodies (mAb) compared to no treatment, and what is the comparative effectiveness between mAb?

Findings Among 3,069 patients, mAb treatment (casirivimab and imdevimab or sotrovimab) was associated with reduced risk of hospitalization or death by 28 days compared to no treatment (risk ratio=0.40, 95% CI: 0.28–0.57). In a Bayesian randomized comparative effectiveness trial of casirivimab and imdevimab vs. sotrovimab in 3,558 patients, the median hospital–free days were 28 days for both groups. Compared to casirivimab-imdevimab, the median adjusted odds ratio for hospital-free days was 0.88 (95% credible interval, 0.70–1.11) for sotrovimab, an 86% probability of inferiority of sotrovimab versus casirivimab and imdevimab, and 79% probability of equivalence.

Meaning In non-hospitalized patients with mild to moderate COVID-19 due to the Delta variant, casirivimab and imdevimab and sotrovimab were associated with reduced risk of hospitalization or death compared to no treatment. The comparative effectiveness of mAbs appeared similar, though prespecified criteria for statistical inferiority or equivalence were not met.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

NCT04790786

Funding Statement

This study did not receive any funding.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

UPMC Quality Improvement Review Committee (Project ID 2882, Project ID 3116, and Project ID 3280) and the University of Pittsburgh Institutional Review Board (STUDY21020179) gave ethical approval for this work.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data produced in the present study are available upon reasonable request to the authors.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted December 27, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Effectiveness of casirivimab and imdevimab, and sotrovimab during Delta variant surge: a prospective cohort study and comparative effectiveness randomized trial
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Effectiveness of casirivimab and imdevimab, and sotrovimab during Delta variant surge: a prospective cohort study and comparative effectiveness randomized trial
David T. Huang, Erin K. McCreary, J. Ryan Bariola, Tami E. Minnier, Richard J. Wadas, Judith A. Shovel, Debbie Albin, Oscar C. Marroquin, Kevin E. Kip, Kevin Collins, Mark Schmidhofer, Mary Kay Wisniewski, David A. Nace, Colleen Sullivan, Meredith Axe, Russell Meyers, Alexandra Weissman, William Garrard, Octavia M. Peck-Palmer, Alan Wells, Robert D. Bart, Anne Yang, Lindsay R. Berry, Scott Berry, Amy M. Crawford, Anna McGlothlin, Tina Khadem, Kelsey Linstrum, Stephanie K. Montgomery, Daniel Ricketts, Jason N. Kennedy, Caroline J. Pidro, Rachel L. Zapf, Paula L. Kip, Ghady Haidar, Graham M. Snyder, Bryan J. McVerry, Donald M. Yealy, Derek C. Angus, Christopher W. Seymour
medRxiv 2021.12.23.21268244; doi: https://doi.org/10.1101/2021.12.23.21268244
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Effectiveness of casirivimab and imdevimab, and sotrovimab during Delta variant surge: a prospective cohort study and comparative effectiveness randomized trial
David T. Huang, Erin K. McCreary, J. Ryan Bariola, Tami E. Minnier, Richard J. Wadas, Judith A. Shovel, Debbie Albin, Oscar C. Marroquin, Kevin E. Kip, Kevin Collins, Mark Schmidhofer, Mary Kay Wisniewski, David A. Nace, Colleen Sullivan, Meredith Axe, Russell Meyers, Alexandra Weissman, William Garrard, Octavia M. Peck-Palmer, Alan Wells, Robert D. Bart, Anne Yang, Lindsay R. Berry, Scott Berry, Amy M. Crawford, Anna McGlothlin, Tina Khadem, Kelsey Linstrum, Stephanie K. Montgomery, Daniel Ricketts, Jason N. Kennedy, Caroline J. Pidro, Rachel L. Zapf, Paula L. Kip, Ghady Haidar, Graham M. Snyder, Bryan J. McVerry, Donald M. Yealy, Derek C. Angus, Christopher W. Seymour
medRxiv 2021.12.23.21268244; doi: https://doi.org/10.1101/2021.12.23.21268244

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (428)
  • Allergy and Immunology (753)
  • Anesthesia (220)
  • Cardiovascular Medicine (3286)
  • Dentistry and Oral Medicine (362)
  • Dermatology (276)
  • Emergency Medicine (478)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1168)
  • Epidemiology (13349)
  • Forensic Medicine (19)
  • Gastroenterology (898)
  • Genetic and Genomic Medicine (5140)
  • Geriatric Medicine (480)
  • Health Economics (781)
  • Health Informatics (3260)
  • Health Policy (1140)
  • Health Systems and Quality Improvement (1189)
  • Hematology (429)
  • HIV/AIDS (1015)
  • Infectious Diseases (except HIV/AIDS) (14618)
  • Intensive Care and Critical Care Medicine (912)
  • Medical Education (476)
  • Medical Ethics (126)
  • Nephrology (522)
  • Neurology (4914)
  • Nursing (262)
  • Nutrition (725)
  • Obstetrics and Gynecology (880)
  • Occupational and Environmental Health (795)
  • Oncology (2517)
  • Ophthalmology (722)
  • Orthopedics (280)
  • Otolaryngology (347)
  • Pain Medicine (323)
  • Palliative Medicine (90)
  • Pathology (542)
  • Pediatrics (1299)
  • Pharmacology and Therapeutics (549)
  • Primary Care Research (555)
  • Psychiatry and Clinical Psychology (4198)
  • Public and Global Health (7489)
  • Radiology and Imaging (1703)
  • Rehabilitation Medicine and Physical Therapy (1010)
  • Respiratory Medicine (979)
  • Rheumatology (479)
  • Sexual and Reproductive Health (496)
  • Sports Medicine (424)
  • Surgery (547)
  • Toxicology (72)
  • Transplantation (235)
  • Urology (204)